VASCULAR
hamburger
product photo

VALVES REPAIRED. LIVES IMPROVED.

Percutaneous mitral valve repair is expanding treatment options for patients suffering from the debilitating symptoms of mitral regurgitation (MR).

MitraClip is the world's first percutaneous mitral valve repair therapy available, providing an option for select patients with MR. Clinical evidence for MitraClip therapy demonstrates:1,2

  • Positive safety profile
  • Reduction in mitral regurgitation
  • Favorable left ventricular remodeling
  • Improvement in patient symptoms
  • Reduction in hospitalizations for heart failure
     

1. Feldman T, Kar S, Elmariah S, et al. Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-Year Results of EVEREST II. J Am Coll Cardiol. 2015;66(25): 2844–54.
2. Maisano F, Franzen O, Baldus S, et al. Percutaneous Mitral Valve Interventions in the Real World: Early and 1-Year Results From the ACCESS-EU, A Prospective, Multicenter, Nonrandomized Post-Approval Study of the MitraClip Therapy in Europe. J Am Coll Cardiol. 2013;62(12): 1052–61.

FIRST-IN-CLASS TECHNOLOGY

MitraClip System

The MitraClip System is the first device available to safely perform percutaneous mitral valve repair.

  • Beating-heart procedure with no cardiopulmonary bypass required
  • Allows for real-time positioning and repositioning to optimize mitral regurgitation reduction
  • Designed to preserve surgical options

MitraClip Steerable Guide Catheter

STEERABLE GUIDE CATHETER

  • 24-French steerable catheter
  • Percutaneous venous access

MitraClip Clip Delivery System

 

CLIP DELIVERY SYSTEM

The Clip Delivery System includes the implant attached to a highly maneuverable delivery catheter, with all controls at the proximal end.

MitraClip Device

MITRACLIP DEVICE

  • Cobalt chromium construction
  • Polyester cover designed to promote tissue growth
  • Magnetic resonance conditional to 3 tesla (T)* 

*Static magnetic field up to 3 T; maximum spatial gradient in static field of 2500 gauss/cm or less; maximum whole-body averaged specific absorption rate (SAR) of 3.0 W/kg for 15 minutes of scanning

SYSTEM SPECIFICATIONS

MitraClip System Specifications

ABOUT MITRAL REGURGITATION

Mitral regurgitation (MR) is a condition in which the heart's mitral valve leaflets do not close tightly. When this happens, blood flows backward from the heart's left ventricle into the left atrium. The heart must then work harder to push blood through the body, which can cause fatigue, shortness of breath and worsening heart failure.

There are two types of mitral regurgitation: degenerative and functional. Degenerative mitral regurgitation, also called primary mitral regurgitation, is caused by damage to the mitral valve leaflets. Functional mitral regurgitation, also called secondary mitral regurgitation, is caused by enlargement of the heart due to heart attack or heart failure.

MR is the most common type of heart valve insufficiency in the United States. Approximately 4 million people have significant mitral valve insufficiency, with an annual incidence of 250,000.1-3 Approximately 50,000 of these patients undergo surgery each year in the United States. Prevalence and incidence are similar in Europe, where it's the second most common type of heart valve disease.4 The disease affects millions of people worldwide.

About Mitral Regurgitation

TREATMENT OPTIONS FOR MITRAL REGURGITATION

MEDICAL:

There are no medications indicated to treat mitral regurgitation, but there are medications used to manage patient symptoms.

SURGICAL:

For symptomatic patients diagnosed with moderate-severe or severe MR, surgery is generally recommended to repair or replace the mitral valve. This typically involves open-heart surgery with the patient on cardiopulmonary bypass. Patients recovering from mitral valve surgery may take several months to regain normal physical function and activity.

PERCUTANEOUS MITRAL VALVE REPAIR:

The MitraClip procedure is minimally invasive and uses catheter-based technology. This new treatment expands the options for selected patients with MR. It has been shown to reduce MR, reverse left ventricular remodeling, improve NYHA functional class, and improve quality of life.5

References:
1. US Census Bureau. Statistical Abstract of the US: 2006, Table 12.
2. Nkomo et al. Burden of Valvular Heart Diseases: A Population-based Study, Lancet, 2006; 368: 1005-11.
3. Patel et al. Mitral Regurgitation in Patients with Advanced Systolic Heart Failure, J of Cardiac Failure, 2004.
4. Iung, B et al. Eur Heart J. 2003;24:1231-1243.
5. Feldman T, Foster E, Qureshi M, et al. The EVEREST II Randomized Controlled Trial: Three Year Outcomes. Transcatheter Cardiovascular Therapeutics; October 22-26, 2012; Miami, FL.

AP2938491-WBO Rev. A

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

YESNO